# A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

Source: https://onco.cc/trials/nct06140836/  
OnCo record `nct06140836` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Repotrectinib and Crizotinib in non-small-cell lung cancer, run by Bristol-Myers Squibb, active and no longer recruiting.

## Summary

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) is a phase 3 interventional study registered as NCT06140836 by Bristol-Myers Squibb, with 190 participants enrolled, started 2023-12-21 and due to reach its primary completion in 2026-03-13. Interventions recorded: Repotrectinib and Crizotinib.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06140836
- Phase: 3
- Setting: Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
- Sponsor: Bristol-Myers Squibb
- Enrolled: 190

## Sources

- ClinicalTrials.gov NCT06140836: https://clinicaltrials.gov/study/NCT06140836

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Crizotinib](https://onco.cc/drugs/crizotinib/), [Repotrectinib](https://onco.cc/drugs/repotrectinib/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct06140836.json